Table 2 A summary of the modifications for the T stage, risk group and CTV following prostate MRI studies in 157 evaluable patients

No change

118 (75)

–

–

Upstaging

33 (21)

10 (6)

11 (7)

 T1c to T2a

10

0

0

 T1c to T2b

10

1 (L → IM)

1 (pSV in CTV1)

 T1c to T2c

3

2 (L → IM)

2 (pSV in CTV1)

 T1c to T3a

2

1 (L → H)

1 (pSV and GED in CTV1, GED in CTV2)

 T2a to T3a

1

0

1 (pSV and GED in CTV1, GED in CTV2)

 T2a to T3b

2

2 (H → VH)

2 (eSV and GED in CTV1, GED in CTV2)

 T2b to T2c

1

0

0

 T2b to T3a

1

1 (IM → H)

1 (GED in CTV1, CED in CTV2)

 T2b to T3b

1

1 (H → VH)

1 (eSV and GED in CTV1, GED in CTV2)

 T3a to T4

2

2 (H → VH)

2 (eSV and GED in CTV1, GED in CTV2)

Downstaging

6 (4)

4 (3)

2 (1)

 T3a to T2a

1

1 (H → IM)

0^a

 T3a to T2b

2

1 (H → IM)

0^a

 T3a to T2c

1

0

0

 T3b to T2c

1

1 (VH → H)

1^a (eSV in CTV1)

 T4 to T2a

1

1 (VH → H)

1^a (eSV in CTV1)